Analysts say Darzalex sales prognosis could be too cautious

Analysts from both US-based Jefferies and Danish bank Sydbank say that the sales forecast for Johnson & Johnson's drug Darzalex, which the company obtained through a licensing agreement with Genmab, is a tad too conservative, perhaps signaling a potential upgrade.

Photo: Tuala Hjarnø / Genmab / PR

The sales of Darzalex have exceeded expectations in the third quarter of the year, surpassing net sales expectations by more than DKK 850 million.

All taken together, Genmab's partner Janssen has achieved sales figures so big that Genmab's own estimate for the 2021 net sales might have been too cautious, say analysts from US-based Jefferies.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs